Cantor Fitzgerald Reaffirms Overweight Rating for Spero Therapeutics (NASDAQ:SPRO)

Cantor Fitzgerald reissued their overweight rating on shares of Spero Therapeutics (NASDAQ:SPRO - Free Report) in a report issued on Thursday, Benzinga reports.

Separately, HC Wainwright reiterated a buy rating and issued a $7.00 price target on shares of Spero Therapeutics in a research note on Monday, March 18th.

Spero Therapeutics Stock Performance

SPRO traded down $0.10 on Thursday, reaching $1.69. The company had a trading volume of 275,940 shares, compared to its average volume of 314,948. Spero Therapeutics has a fifty-two week low of $0.99 and a fifty-two week high of $2.00. The stock has a market cap of $91.04 million, a P/E ratio of 4.02 and a beta of 0.55. The company's fifty day moving average is $1.62 and its 200 day moving average is $1.38.

Institutional Trading of Spero Therapeutics

Several large investors have recently made changes to their positions in SPRO. Bank of America Corp DE lifted its stake in Spero Therapeutics by 132.0% in the 1st quarter. Bank of America Corp DE now owns 18,417 shares of the company's stock valued at $27,000 after purchasing an additional 10,479 shares during the last quarter. CI Private Wealth LLC bought a new position in Spero Therapeutics in the 4th quarter valued at approximately $30,000. Jane Street Group LLC bought a new position in Spero Therapeutics in the 3rd quarter valued at approximately $31,000. UBS Group AG raised its stake in shares of Spero Therapeutics by 2,934.2% during the third quarter. UBS Group AG now owns 22,908 shares of the company's stock valued at $46,000 after acquiring an additional 22,153 shares during the last quarter. Finally, Citadel Advisors LLC bought a new position in shares of Spero Therapeutics during the fourth quarter valued at $47,000. Institutional investors and hedge funds own 25.60% of the company's stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, a novel oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease.